IceCure's ProSense™ Cryoablation Sees Growing Commercial Adoption in Brazil Following FDA Clearance
ICCM has more than doubled off its 52-week low of $2.12.
Summary
IceCure Medical is experiencing expanding commercial adoption of its ProSense™ cryoablation system in Brazil, with procedures already being performed for various cancers. This growth is attributed to the recent U.S. FDA marketing authorization for early-stage breast cancer, which has boosted awareness and interest among Brazilian physicians. This positive commercial update provides a welcome counterpoint to recent corporate actions, including a 1-for-30 reverse stock split, a private placement, and an F-3 filing for share resale, all of which could be dilutive. Ongoing independent studies in Brazil (750 patients) and a planned study in France (900 patients) could further drive adoption and clinical validation.
At the time of this announcement, ICCM was trading at $5.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15M. The 52-week trading range was $2.12 to $42.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.